Monitor the AXPAXLI NDA submission in Q4 2026 and the FDA's acceptance decision. The SOL-R interim Week 52 safety analysis in Q4 2026 will be a key catalyst. Cash runway into 2028 provides a long development horizon, but the widening net loss and rising R&D spend warrant attention to cash burn rate.
Drug in focus
OCUL drug pipeline →OTX-TKI
▲ Bullish Named in this press release- Impact
- Phase
- Phase 3 (pivotal completed; NDA submission imminent)
- Time to market
- If the NDA is submitted in Q4 2026 as planned, a standard FDA review would take approximately 10 months, suggesting a potential approval decision in late 2027. A priority review (possible under 505(b)(2) pathway) could shorten this to 6-8 months, potentially yielding a mid-2027 decision.
- Next catalyst
- None dated
What to watchWatch for the NDA submission announcement, expected any week given the Q4 2026 timeline confirmed on the November 9 earnings call. After submission, the next catalysts are FDA acceptance (60-day filing review) and PDUFA date assignment. A standard review would set a decision in late 2027; a priority review could accelerate to mid-2027. The stock's wide gap between current price ($6.85) and analyst targets ($25.45 mean) reflects both the binary regulatory risk and the potential for significant upside if the NDA is accepted and reviewed favorably.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $6.85entry
- T+1 · 7d ago −3.50%α −3.14% · $6.61
- T+5 · 18h ago −12.26%α −10.57% · $6.01
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix reported Q3 2026 net loss of $(0.42) per share on revenue of $12.9M, missing the consensus EPS estimate of $(0.35) and revenue estimate of $14.3M. The company reiterated its AXPAXLI NDA submission for wet AMD is on track for Q4 2026, with $530.6M cash providing runway into 2028.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $(94.8)M or $(0.42)/share vs consensus $(0.35)/share
- Q3 2026 total revenue $12.9M vs consensus $14.3M and prior year $14.5M
- Cash balance $530.6M as of Sep 30, 2026, expected runway into 2028
- AXPAXLI NDA submission for wet AMD on track for Q4 2026 under 505(b)(2) pathway
- SOL-R primary endpoint moved to Week 40; topline results expected Q1 2028
- R&D expenses $74.8M in Q3 2026 vs $52.4M in Q3 2025, up 42.8%
- Selling and marketing expenses $15.7M vs $13.1M in prior year quarter
Financial Impact
EPS miss of $(0.42) vs $(0.35) consensus; revenue miss of $12.9M vs $14.3M consensus; net loss widened to $(94.8)M from $(69.4)M YoY
Risk Factors
- AXPAXLI NDA may not be accepted for filing or may not receive FDA approval
- SOL-R trial design changes and interim safety analysis could introduce uncertainty
- Rising R&D and SG&A expenses are accelerating cash burn despite $530.6M balance
- Revenue decline from DEXTENZA product sales may continue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398240 |
Track record
20 reports on OCUL
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Viewing Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers